Search Results 7971-7980 of 33402 for oral

  1. Evaluate The Safety, Tolerability, Pharmacokinetics And Efficacy Of BL-M05D1 In Subjects With Solid Tumors - Mayo Clinic

    Subjects on stable oral antimicrobials with no clinical or laboratory evidence of active infection are eligible 21. Subjects who are pregnant, breastfeeding ...

  2. Diabetic neuropathy: Can dietary supplements help? - Mayo Clinic

    Along with a healthy diet, some vitamin and antioxidant products might play a role in preventing or slowing this common diabetes complication.

  3. PR3-AAV Resilient Remission or PRRR - Mayo Clinic

    ... (oral, injectable, implant or ring); 3) barrier contraceptives (condom or diaphragm) with spermicide; or 4) abstinence. Exclusion Criteria: - Diagnosis with ...

  4. A Study to Test Sacituzumab Govitecan Therapy in Patients with HER2-Negative Breast Cancer and Brain Metastases - Mayo Clinic

    Participants who are able to switch to low molecular weight heparin (LMWH) or direct oral anticoagulants (DOACs) prior to date of registration (and plan to ...

  5. Safety and Efficacy Study of Filgotinib, GS-9876 and Tirabrutinib in Adults With Active Sjogren's Syndrome - Mayo Clinic

    Stable dose (defined as no change in prescription for at least 4 weeks prior to Day 1) of NSAIDs, HCQ, MTX and/or oral corticosteroids is permitted during ...

  6. Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer - Mayo Clinic

    Able to swallow oral formulation of the study agent; Hemoglobin >= 9 g/dL; Platelet count >= 75,000/mm^3; Creatinine =< 1.5 x upper limits of normal (ULN) ...

  7. Pazopanib Hydrochloride in Treating Patients with Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma - Mayo Clinic

    Any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation ...

  8. A Study of Mavacamten in Patients with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM or EXPLORER-HCM Trials - Mayo Clinic

    ... oral, implantable, or injectable route of administration;; intrauterine device (IUD);; intrauterine hormone-releasing system (IUS);; bilateral tubal occlusion ...

  9. Wondering about a marketing claim that uses the Mayo Clinic brand?

    Yet, from time to time, we hear from concerned consumers, our patients and employees, or the media about materials they see in the marketplace where a non-Mayo ...

  10. Myomectomy - Doctors & Departments - Mayo Clinic

    Oral gonadotropin-releasing hormone antagonists for the treatment of uterine leiomyomas. Obstetrics & Gynecology. 2023; doi:10.1097/AOG.0000000000005145 ...